Top 5 Drug Type | Count |
---|---|
Diagnostic radiopharmaceuticals | 3 |
Small molecule drug | 3 |
Monoclonal antibody | 1 |
Radionuclide Drug Conjugates (RDC) | 1 |
Top 5 Target | Count |
---|---|
CTSL(Cathepsin L) | 1 |
CB(Cannabinoid receptor) | 1 |
Target |
Mechanism ACVR2A modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date26 Mar 2024 |
Target |
Mechanism CB antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date25 Jun 2018 |
Target- |
Mechanism PET imaging |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CH |
First Approval Date01 Nov 2016 |
Start Date01 Feb 2025 |
Sponsor / Collaborator |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date01 Oct 2024 |
Sponsor / Collaborator ![]() [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
FLUORODOPA F-18 | Parkinsonian Disorders More | Approved |
AMMONIA N-13 | Coronary Artery Disease More | Approved |
Fludeoxyglucose F-18 | Epilepsy More | Approved |
Cannabidiol ( CB ) | Osteoarthritis, Knee More | Phase 2 |
Anti-pCTS-L monoclonal antibody(Feinstein Institutes for Medical Research) ( CTSL ) | Sepsis More | Discovery |